Premium
Factors Affecting Compliance and Persistence with Treatment for Hepatic Encephalopathy
Author(s) -
Neff Guy
Publication year - 2010
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.30.pt2.22s
Subject(s) - rifaximin , medicine , lactulose , hepatic encephalopathy , medical prescription , adverse effect , cirrhosis , persistence (discontinuity) , emergency medicine , disease , intensive care medicine , pediatrics , nursing , antibiotics , geotechnical engineering , microbiology and biotechnology , biology , engineering
Noncompliance with treatment protocols produces an increased burden on the health care system. Reports show that 23% of annual admissions to nursing homes in the United States (380,000 patients) are due to noncompliance, resulting in overall costs of over $31 billion. More than 10% of all patients (3.5 million) are hospitalized each year due to complications related to noncompliance, with over $15 billion spent. In addition, nearly half of the 2 billion prescriptions filled each year are not taken correctly. Patients with cirrhosis and hepatic encephalopathy who are prescribed lactulose experience a greater frequency of adverse effects, require more hospitalizations, and suffer more disease recurrence than those prescribed rifaximin.